Cell Genesys news from FierceBiotech
News
GVAX questions depress Dendreon shares
Deaths force halt to Cell Genesys cancer vaccine trial
Takeda makes $8.8B bid for Millennium
Takeda makes $8.8B bid for Millennium
Cell Genesys scores $320M blockbuster deal
C&L: Stonehouse tapped to run Biocryst

BioCryst Pharmaceuticals announced that Jon P. Stonehouse, has been appointed CEO and a member of the company's board of directors. Stonehouse succeeds Charles E. Bugg, Ph.D., founder and former CEO who previously announced his intention to retire in 2007. In his new role, Dr. Bugg will become non-executive chairman of …
Read more...C&L: Cell Genesys COO Vallner resigns

Cell Genesys announced that Joseph J. Vallner, Ph.D., the company's president and COO, has resigned to become the CFO of an early-stage, private biotechnology company.
Le@p Technology has named Dr. Donald J. Ciappenelli as CEO and chairman.
Access Genetics has named industry veteran …
Read more...Blair touts biotech biz in San Francisco sit-down
Singling out Genentech for high praise, British Prime Minister Tony Blair sat down with a group of biotech execs in San Francisco yesterday to highlight his own commitment to boosting Britain's drug development industry. In a marked break with the Bush administration, Blair also emphasized the need for more research work in embryonic stem cells. A number of British biotech officials feel their country's research groups have stolen a march on the U.S., pushing ahead while stem cell work in …
Read more...ALSO NOTED: Cadence files $86.3M IPO; Chutes & Ladders: Merck exec steps down; and much more...
> Yesterday, Cadence Pharmaceuticals filed an $86.3 million IPO with the SEC. The company currently has two Phase III products in development. Release
> Cangene today has filed an NDA for its recombinant human growth hormone product (rhGH) Accretropin with the FDA. Accretropin combats short stature in children with growth hormone deficiency and girls with Turner Syndrome. …
Read more...ALSO NOTED: Nektar gains fast track for lung infection drug; Vertex reports positive hep C data; and much more...
> Nektar Therapeutics was given a fast-track designation for its lung infection prevention drug. Report
> Vertex announced that all 12 patients in a mid-stage trial of its VX-950 hepatitis C therapy showed no detectable signs of the virus after 28 days of therapy. Report
> ViroPharma announced …
Read more...Get more Cell Genesys coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets

